• FDA Authorizes a Second Artificial Pancreas System

    In-depth on Tandem’s Advanced Hybrid Closed-Loop System

    Tandem’s FDA-approved Control IQ system is a major improvement over other loop systems and is expected to hit the market in early 2020


    Dexcom G6


    In a win for all people with type 1 diabetes (even those who won’t directly benefit from this closed-loop system), the FDA has approved Tandem’s new Control IQ software for release in 2020.

    This new automated glycemic control algorithm is just the second hybrid closed-loop system available to patients with an FDA clearance. And it promises tighter control, easier usability, and more customization than the current 670g automated system from Medtronic.


    New Hybrid Closed Loop Technology

    Artificial Pancreas System

  • New Insulin Affordability Programs

    Include $99 Insulin in the US from Novo Nordisk


    $99 Cash Card Program for Analog Insulins:

    Using My$99Insulin, people with diabetes will be able to purchase up to three vials or two packs of FlexPen/FlexTouch pens with any combination of Novo Nordisk analog insulins (NovoLog, Tresiba, Fiasp) for $99. Depending on the brand, this is about 3000-3800 units of insulin. The company suggests that this supply of insulin will cover the monthly needs of most people with diabetes. People can use the My$99insulin card as often as they need to.